A federal judge in Hawaii indefinitely extended on Wednesday an order blocking enforcement of President Donald Trump's revised ban.
Hedge fund impresario John Paulson, struggling from losses and investor outflows in 2016, has drastically slashed bonuses to top executives at his once high-flying investment firm, the Fox Business Network has learned.
A pioneer’s descendant could pocket a bundle from his strange inheritance.
Stock markets were broadly lower Thursday following a mixed session in the U.S. overnight, with shares in Shanghai staging their biggest intraday drop this year.
A restraining order blocking President Donald Trump's revised travel ban was extended indefinitely Wednesday night by a federal judge in Hawaii.
Some of the biggest household names are threatening to pull their ad spend from YouTube if the company fails to address the problem of objectionable content.
Westinghouse Electric Co's financial distress sparked a feeding frenzy among Wall Street lenders keen to give the nuclear developer a lifeline while it reorganizes in bankruptcy, according to court papers and people familiar with the matter.
PC market leaders Lenovo, HP, and Apple are good dividend plays.
Check Point Software, Palo Alto Networks, and Fortinet are all market leaders in the next-gen firewall market.
These online retailers are pouring billions of dollars into India, but who will come out on top?
The semiconductor companys legal problems could meaningfully damage its business model and financial performance.
The coffee giant plans to significantly ramp up hiring over the coming years. Revenue and profit growth should follow.
Why GameStop, Carter's, and PCM stocks stand out as potential winners in a struggling retailing industry.
In a mixed market, these winners climbed higher. Here's what investors need to know.
These stocks saw unusual declines today. Here's what investors need to know.
RH and Sonic stocks posted market-beating gains as indexes had a mixed showing.
Looking for solid health insurance stock picks? Check out Aetna, Centene, and UnitedHealth Group.
Looking for biotech stocks with promising growth potential? Check out Omeros, Ionis Pharmaceuticals, and Celgene.
Time -- and a recession -- might be a better cure for GM's ailing stock price than some fancy financial engineering.
A small Georgia bank has emerged as the potential savior of Bass Pro Shops's $4.5 billion takeover of outdoor-goods retailer Cabela's Inc., according to people familiar with the matter.
The repositioned shale driller is ready to start growing again.
Microsoft, IBM, Oracle, and HPE all offer investors exposure to the cloud market with reliable dividend payments.
Shares of F5 Networks Inc. slumped 3.4% Wednesday, enough to pace the S&P 500 decliners, after Deutsche Bank turned bearish on the business networking company, citing expectations of slowing product and services revenue growth.
Johnson & Johnson, Amgen, and Gilead Sciences currently rank as the most cash-rich drugmakers -- but Pfizer could knock one of them out of its spot soon.
If you regularly contribute to your retirement accounts, that's fantastic -- but you also need to make sure that those funds are safe.
But don't expect it to do so anytime soon.
Oil prices rose Wednesday to finish at their highest level in roughly three weeks.
Darden Restaurants receives mixed Wall Street coverage after its latest quarter, but its latest acquisition of Cheddar's Scratch Kitchen is the right thing to do.
Citizens Financial Group Inc. shares took a sharp turn down Wednesday, after a Wall Street Journal report that employees fabricated meetings with customers to meet goals set by the bank.
Ready to open an IRA? See how popular discount brokers TradeKing and Fidelity compare for retirement investors.
Mylan NV shares sank 2.0% in afternoon trade Wednesday after the company said the Food and Drug Administration failed to approve its generic version of the asthma medication Advair Diskus, which is manufactured by GlaxoSmithKline .
Lionsgate's most important 2017 film has delivered a solid, but not spectacular, debut.
Shares of the travel rating and booking company have taken a beating in the past couple of years. Is it time to buy in for future growth, or will the dip just get deeper?